|
 The pill is approved in Britain for use in people with mild to
moderate COVID-19, but it is not known whether it would work in
patients hospitalised with severe illness, researchers of the
RECOVERY trial said on Monday.
The study will compare 800 mg doses of molnupiravir, given twice
daily for five days, with standard care for adult patients in
hospitals because of COVID-19.
In 2020, the same scientists conducting the large trial showed that
dexamethasone was able to save the lives of COVID patients in what
was called a "major breakthrough" in the coronavirus pandemic.
[to top of second column] |
 "Adding molnupiravir (to the
study) will allow us to study this drug on its
own, but also in combination with other COVID-19
treatments," said Peter Horby, joint chief
investigator of the trial and Oxford University
professor.
Treatments that have been or being tested in the
RECOVERY trial include arthritis drug
tocilizumab, steroid dexamethasone, common
antibiotic azithromycin, painkiller aspirin, and
antibody treatments from Regeneron and GSK-Vir.
(Reporting by Amna Karimi and Pushkala Aripaka
in Bengaluru; Editing by Shailesh Kuber)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
